No­var­tis pledges $100M to malar­ia ef­forts; Lil­ly, Boehringer out­lines new Jar­diance kid­ney tri­al at Ox­ford

→ No­var­tis is ded­i­cat­ing $100 mil­lion to fight malar­ia, com­mit­ting to ad­vance R&D of next-gen treat­ments ad­dress­ing re­sis­tance while al­so im­ple­ment­ing a pric­ing strat­e­gy that max­i­mizes ac­cess. The com­mit­ment fol­lows two decades of in­volve­ment in the field, which has built up No­var­tis’ malar­ia pipeline that now in­cludes Phase II as­sets KAF156 and KAE609. The new in­vest­ment is ex­pect­ed to sus­tain a glob­al clin­i­cal tri­al pro­gram for these as­sets, as well as oth­er pipeline ac­tiv­i­ties, through 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER